A first case of childhood chronic inflammatory demyelinating polyneuropathy associated with alopecia universalis


      Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired demyelinating disease of the peripheral nervous system with unknown etiology. Alopecia universalis, an advanced form of alopecia areata (AA), is a condition characterized by complete hair loss. Here we report the first case of childhood CIDP associated with AA who was successfully treated with a combination of intravenous immunoglobulin (IVIg) and corticosteroids.

      Case report

      This case describes a nine-year-old Japanese girl who developed alopecia, progressive muscle weakness, and eventually loss of walking ability (at ages 2, 4, and 7, respectively). She was treated with IVIg and prednisolone combination therapy, which improved muscle weakness and alopecia. She was positive for serum IgG-GM2 type anti-glycolipid antibodies, which may be associated with this rare combination of diseases.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dalakas M.C.
        Advances in the diagnosis, pathogenesis and treatment of CIDP.
        Nat Rev Neurol. 2011; 7: 507-517
        • Lee H.H.
        • Gwillim E.
        • Patel K.R.
        • Hua T.
        • Rastogi S.
        • Ibler E.
        • et al.
        Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis.
        J Am Acad Dermatol. 2020; 82: 675-682
        • Simakou T.
        • Butcher J.P.
        • Reid S.
        • Henriquez F.L.
        Alopecia areata: A multifactorial autoimmune condition.
        J Autoimmun. 2019; 98: 74-85
        • Strazzulla L.C.
        • Wang E.H.C.
        • Avila L.
        • Lo Sicco K.
        • Brinster N.
        • Christiano A.M.
        • et al.
        Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis.
        J Am Acad Dermatol. 2018; 78: 1-12
        • Sterkens A.
        • Lambert J.
        • Bervoets A.
        Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.
        Clin Exp Med. 2021; 21: 215-230
        • Waśkiel‐Burnat A.
        • Kołodziejak M.
        • Sikora M.
        • Stochmal A.
        • Rakowska A.
        • Olszewska M.
        • et al.
        Therapeutic management in paediatric alopecia areata: A systematic review.
        J Eur Acad Dermatol Venereol. 2021; 35: 1299-1308
        • Zhou C.
        • Li X.
        • Wang C.
        • Zhang J.
        Alopecia areata: an update on etiopathogenesis, diagnosis, and management.
        Clin Rev Allergy Immunol. 2021; 61: 403-423
        • Van den Bergh P.Y.K.
        • Hadden R.D.M.
        • Bouche P.
        • Cornblath D.R.
        • Hahn A.
        • Illa I.
        • et al.
        European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision.
        Eur J Neurol. 2010; 17: 356-363
        • Berger J.R.
        • Gallo B.
        Chronic inflammatory polyradiculoneuropathy associated with alopecia universalis.
        Muscle Nerve. 1998; 21: 124-125
        • Machino Y.
        • Nakayama S.
        • Tomimoto H.
        A case of multifocal acquired demyelinating sensory and motor neuropathy with whole body alopecia chronic inflammatory demyelinating polyradiculoneuropathy(CIDP) 1.
        Rinsho Shinkeigaku. 2014; 54: 507-510
        • Sanvito L.
        • Wong S.L.
        • Rajabally Y.A.
        Chronic inflammatory demyelinating polyneuropathy associated with alopecia totalis and Sjogren syndrome.
        Muscle Nerve. 2012; 45: 762-763
        • Willison H.J.
        • Yuki N.
        Peripheral neuropathies and anti-glycolipid antibodies.
        Brain. 2002; 125: 2591-2625
        • Yuki N.
        • Hartung H.P.
        Guillain-Barre syndrome.
        N Engl J Med. 2012; 366: 2294-2304
        • Hu W.
        • Xin Y.
        • He Z.
        • Zhao Y.
        Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis.
        Brain Behav. 2018; 8: e01115
        • Adrichem M.E.
        • Bus S.R.
        • Wieske L.
        • Mohammed H.
        • Verhamme C.
        • Hadden R.
        • et al.
        Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study.
        Eur J Neurol. 2020; 27: 506-513
        • Bus S.R.M.
        • Zambreanu L.
        • Abbas A.
        • Rajabally Y.A.
        • Hadden R.D.M.
        • de Haan R.J.
        • et al.
        Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
        Trials. 2021; 22: 155
        • van Schaik I.N.
        • Eftimov F.
        • van Doorn P.A.
        • Brusse E.
        • van den Berg L.H.
        • van der Pol W.L.
        • et al.
        Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial.
        Lancet Neurol. 2010; 9: 245-253